IMUX
IMMUNIC, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.85
+3.22%Oct 29, 2026, 10:30 UTC
IMMUNIC, INC. announced that it will host a virtual R&D Day focused on progressive multiple sclerosis on November 5, 2026, at 12:30 p.m. ET.
Source:Oct 21, 2026, 11:00 UTC
Immunic announced that new clinical, biomarker and preclinical data for vidofludimus calcium are being presented in four posters at the MSToronto2026 meeting.
Source:Oct 19, 2026, 12:47 UTC
IMMUNIC, INC. appointed Jaa Roberson as its first Chief People Officer, reporting to CEO Erik Lundgren and joining the executive leadership team.
Source:Oct 7, 2026, 12:00 UTC
Immunic announced that four abstracts on clinical, biomarker and preclinical data for investigational vidofludimus calcium were accepted for presentation at MSToronto2026.
Sep 11, 2026, 21:27 UTC
Duane Nash resigned as a member of the Board of Directors of Immunic, Inc., effective September 10, 2026.
Source:Sep 2, 2026, 12:54 UTC
Immunic Inc announced it will host a virtual R&D day on September 9, 2026, focused on relapsing multiple sclerosis, ahead of expected topline results from its Phase 3 ENSURE trials by end of 2026.
Source:Aug 11, 2026, 10:30 UTC
Immunic, Inc. reported financial results for the second quarter ended June 30, 2026.